Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
O95998
UPID:
I18BP_HUMAN
Alternative names:
Tadekinig-alfa
Alternative UPACC:
O95998; B3KUZ0; B7WPK4; O95993; O96027; Q9NZA9; Q9UBR7
Background:
Interleukin-18-binding protein, also known as Tadekinig-alfa, plays a crucial role in modulating immune responses. By binding to IL-18, it effectively inhibits the cytokine's activity, thereby regulating the early TH1 cytokine response, which is pivotal in immune defense mechanisms.
Therapeutic significance:
The protein's involvement in fulminant viral hepatitis, a severe liver disease, underscores its potential as a therapeutic target. Understanding the role of Interleukin-18-binding protein could open doors to novel treatments for this life-threatening condition.